Year: 2025
Type: article
Abstract: Endocrine therapy remains the cornerstone for the treatment of advanced and metastatic hormone-receptor-positive, HER2-negative (HR + /HER2 - ) breast cancer. The introduction of cyclin-dependent kinase-4/6 (CDK4/6) inhibitors, palbociclib, ribociclib, and abemaciclib, into clinical practice, has enhanced the clinical benefit of endocrine therapy through the inhibition of retinoblastoma (RB) phosphorylation. This has translated into prolonged progression-free intervals and overall survival [ 1 , 2 , 3 ].
Source: Cell Death and Disease
Authors: Oliver Kepp, Guido Kroemer
Institutions: Centre National de la Recherche Scientifique, Inserm, Institut Universitaire de France, Université Paris Cité, Université Paris-Saclay, Institut Gustave Roussy, Sorbonne Université, Centre de Recherche des Cordeliers, Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,990
Funders: Association pour la Recherche sur le Cancer, Seerave Foundation, Equipex, European Commission, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Fondation pour la Recherche Médicale, Ligue Contre le Cancer, Institut Universitaire de France, Institut National Du Cancer, Institut Gustave-Roussy, Direction Générale de l’offre de Soins, Ministère des Solidarités et de la Santé, Fondation Gustave Roussy, Université de Paris, HORIZON EUROPE European Innovation Council, HORIZON EUROPE European Research Council
Awards: G1190173965, Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation., Next-generation phenotypic screening for oncological applications, G1963894250, Lung cancer prevention and interception, Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception., Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response., Mitochondrial copper targeting to modulate inflammatory macrophages, G434337789, G4656594441, G4707887143, Microbiota-centered interventions to solve antibiotics-induced primary resistance to immune checkpoint inhibitors, Immunogenic cell death (ICD) in the cancer-immune dialogue, Energizing the failing heart, G7041469554, G7562053067, G82931992, G8471630636, Université de Paris, The RUSH (retention using selective hooks) system: a chemical-genetic system for the in vivo manipulation of intercellular communication
OpenAlex ID: W4416222294